Evidence map›Paper›PMID 37007076›Full record

ArticleFrontiers in oncology2023

Exploiting embryonic niche conditions to grow Wilms tumor blastema in culture.

Heather M Wojcik, Harold N Lovvorn, Melinda Hollingshead, Janene Pierce, Howard Stotler, Andrew J Murphy, Suzanne Borgel, Hannah M Phelps, Hernan Correa, Alan O Perantoni

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Heather M WojcikCancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, MD, United States.
Harold N LovvornDepartment of Pediatric Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
Melinda HollingsheadBiological Testing Branch/Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, United States.
Janene PierceDepartment of Pediatric Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
Howard StotlerLeidos Biomedical Research, National Cancer Institute at Frederick, Frederick, MD, United States.
Andrew J MurphyDepartment of Pediatric Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
Suzanne BorgelLeidos Biomedical Research, National Cancer Institute at Frederick, Frederick, MD, United States.
Hannah M PhelpsDepartment of Pediatric Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
Hernan CorreaDivision of Pediatric Pathology, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
Alan O PerantoniCancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, MD, United States.
National Cancer Institute · USMonroe Carell Jr. Children's Hospital · USVanderbilt University · USLeidos (United States) · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
CITED1 nuclear localization and its role in Wilms' tumor pathogenesisR00CA135695 · NCI · VANDERBILT UNIVERSITY · PI LOVVORN, HAROLD NEWTON · 2010 to 2012
$732k
CCR NIH HHS HHSN261200800001CNCATS NIH HHS UL1 TR002243NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA068485NCI NIH HHS R00 CA135695NCI NIH HHS T32 CA106183
6 · The paper itself

Abstract

Introduction: Wilms Tumor (WT), or nephroblastoma, is the most common pediatric kidney cancer. Most WTs display a "favorable" triphasic histology, in which the tumor is comprised of blastemal, stromal, and epithelial cell types. Blastemal predominance after neoadjuvant chemotherapy or diffuse anaplasia ("unfavorable" histology; 5-8%) portend a worse prognosis. Blastema likely provide the putative cancer stem cells (CSCs), which retain molecular and histologic features characteristic of nephron progenitor cells (NPCs), within WTs. NPCs arise in the metanephric mesenchyme (MM) and populate the cap mesenchyme (CM) in the developing kidney. WT blastemal cells, like NPCs, similarly express markers, SIX2 and CITED1. Tumor xenotransplantation is currently the only dependable method to propagate tumor tissue for research or therapeutic screening, since efforts to culture tumors Methods: Previously, our lab developed niche conditions that support the propagation of murine NPCs in culture. Applying similar conditions to WTs, we assessed our ability to maintain key NPC "stemness" markers, SIX2, NCAM, and YAP1, and CSC marker ALDHI in cells from five distinct untreated patient tumors. Results: Accordingly, our culture conditions maintained the expression of these markers in cultured WT cells through multiple passages of rapidly dividing cells. Discussion: These findings suggest that our culture conditions sustain the WT blastemal population, as previously shown for normal NPCs. As a result, we have developed new WT cell lines and a multi-passage

Indexed as

blastemacancer stem cellcell culturemetanephric mesenchymeWilms Tumor

Identifiers

PMID37007076
PMCPMC10061139
OpenAlexW4327618773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.